{"schema_version":"1","generated_at":"2026-11-03T23:37:47.431Z","data_as_of":null,"url":"https://www.findmykol.com/kol/peter-barth","json_url":"https://www.findmykol.com/kol/peter-barth/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"peter-barth","name":"Peter Barth","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Lifespan","institution_url":"https://www.findmykol.com/institution/lifespan","city":"Providence","state":"RI","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1124382445","orcid":"0000-0003-2216-8376","openalex":"A5021289915"},"summary":"Peter Barth is an Oncology physician affiliated with Lifespan. OpenAlex indexes 48 publications with 301 citations (h-index 9).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":48,"cited_by_count":301,"h_index":9,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":8,"program_years":{"first":2021,"last":null},"rows_total":14,"shown":3,"withheld":11,"rows":[{"payer":"Janssen Scientific Affairs, LLC","program_year":2024,"amount_usd":150,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1124382445"},{"payer":"PFIZER INC.","program_year":2023,"amount_usd":5725.62,"payment_count":6,"source_url":"https://openpaymentsdata.cms.gov/search?query=1124382445"},{"payer":"E.R. Squibb & Sons, L.L.C.","program_year":2023,"amount_usd":3087.5,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1124382445"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1124382445","source":"payments"},"publications":{"total":48,"shown":5,"withheld":43,"matched_by":"OpenAlex author record","recent":[{"title":"Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM).","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.tps7567","status":"verified"},{"title":"Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15)","year":2025,"journal":"Cancers","source_url":"https://doi.org/10.3390/cancers17152433","status":"verified"},{"title":"Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients","year":2023,"journal":"Cancers","source_url":"https://doi.org/10.3390/cancers15174359","status":"verified"},{"title":"Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study","year":2023,"journal":"The Oncologist","source_url":"https://doi.org/10.1093/oncolo/oyad017","status":"verified"},{"title":"Ibrutinib in Combination with Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma (AFT-15)","year":2023,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2023-187296","status":"verified"}],"source":"works"},"contact":{"address_1":"593 EDDY ST","city":"Providence","state":"RI","zip":"029034923","phone":"401-444-5435","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1124382445","source":"identity"},"similar":[{"name":"Christina Bandera","slug":"christina-bandera","institution":"Lifespan","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/christina-bandera","json_url":"https://www.findmykol.com/kol/christina-bandera/profile.json"},{"name":"Vicky Cheng","slug":"vicky-cheng","institution":"Lifespan","specialty":"Endocrinology, Diabetes & Metabolism","url":"https://www.findmykol.com/kol/vicky-cheng","json_url":"https://www.findmykol.com/kol/vicky-cheng/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":11,"publications":43}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2021-06-09","provider_certified":"2021-06-09","collected_at":"2026-11-03T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}